South African Company to Produce Pfizer Vaccine in Africa for First Time 

As cases surge, Africa has struggled to obtain more vaccine doses.

Latest News

A clinical trials patient receives a dose of AstraZeneca test vaccine at the University of Witwatersrand' Soweto's Chris Sani Baragwanath Hospital facility outside Johannesburg Nov. 30, 2020. South Africa is scrambling to come up with a new vaccination strategy to combat COVID-19 following its suspension of the rollout of the AstraZeneca vaccine, after a preliminary test showed weak results in protecting the variant dominant in this country. Among the possibilities being considered are giving one dose of AstraZeneca in the hopes it will protect against severe disease and death from the variant. (AP Photo/Jerome Delay)

The Pfizer-BioNTech COVID-19 vaccine will be produced in South Africa for the first time, the company announced Wednesday.

The Cape Town-based Biovac Institute will produce the vaccine for Pfizer starting in 2022, the Associated Press reported. The company will distribute the vaccine throughout Africa.

As cases surge, Africa has struggled to obtain more vaccine doses. Biovac set a goal of creating 100 million doses annually.

Vaccinations in South Africa have increased, with 1.4 million people being fully vaccinated. Over 220,000 people are getting COVID-19 shots on weekdays, per AP. The country hopes that 67% of its population will be vaccinated by February 2022.

RELATED: South Africa starts jabs for elderly as virus surge looms